Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a Phase I open-label dose escalation study
Roger J. Laham, Nicholas A. Chronos, Marilyn Pike, Mark E. Leimbach, James E. Udelson, Justin D. Pearlman, Roderic I. Pettigrew, M. J. Whitehouse, Carl Yoshizawa, Michael Simons
Dive into the research topics of 'Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a Phase I open-label dose escalation study'. Together they form a unique fingerprint.